Advertisement

Controversies in the Therapy of Low-Grade Gliomas

  • Ivan D. CarabenciovEmail author
  • Jan C. Buckner
Neuro-oncology (GJ Lesser, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Neuro-oncology

Opinion statement

In the context of the new WHO classification system, all low-grade gliomas must have an IDH mutation, with or without 1p/19q codeletion. Upon discovery of the tumor, maximal safe surgical resection is the most appropriate first step due to the current inability to differentiate between IDH mutant and IDH wild–type tumors by imaging alone. In the postoperative setting, based on the synthesis and interpretation of the available data, we recommend utilizing conventional radiation therapy and PCV in all high-risk–low-grade gliomas. For patients felt to be in a low risk category, we recommend maintaining a low threshold to initiate treatment. In the setting of tumor recurrence, consideration of all treatment options is reasonable, but treatment with alkylator therapy has the strongest supporting data.

Keywords

Low-grade glioma Controversy PCV Temozolomide IDH mutation 

Notes

Compliance with Ethical Standards

Conflict of Interest

Ivan D. Carabenciov and Jan C. Buckner declare they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Louis DN, Perry A, Reifenberger G, Von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20.PubMedGoogle Scholar
  2. 2.
    Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet. 2015;47(5):458–68.PubMedGoogle Scholar
  3. 3.
    Labussiere M, Idbaih A, Wang X-W, Marie Y, Boisselier B, Falet C, et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology. 2010;74(23):1886–90.PubMedGoogle Scholar
  4. 4.
    Chan AK-Y, Yao Y, Zhang Z, Shi Z, Chen L, Chung NY-F, et al. Combination genetic signature stratifies lower-grade gliomas better than histological grade. Oncotarget. 2015;6(25):20885.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Tabouret E, Nguyen AT, Dehais C, Carpentier C, Ducray F, Idbaih A, et al. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Acta Neuropathol. 2016;132(4):625–34.PubMedGoogle Scholar
  6. 6.
    Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer. 1997;79(7):1381–93.PubMedGoogle Scholar
  7. 7.
    van den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective. Acta Neuropathol. 2010;120(3):297–304.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Cancer Genome Atlas Research N, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):2481–98.Google Scholar
  9. 9.
    Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499–508.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Liu X-Y, Gerges N, Korshunov A, Sabha N, Khuong-Quang D-A, Fontebasso AM, et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol. 2012;124(5):615–25.PubMedGoogle Scholar
  11. 11.
    Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, An J, et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol. 2012;226(1):7–16.PubMedGoogle Scholar
  12. 12.
    Cryan JB, Haidar S, Ramkissoon LA, Bi WL, Knoff DS, Schultz N, et al. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget. 2014;5(18):8083.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Cohen AL, Holmen SL, Colman H. IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep. 2013;13(5):345.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016;17(11):1521–32.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, et al. Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG oncology/RTOG 0424 trial. JAMA Oncol. 2018;4:1405.PubMedGoogle Scholar
  16. 16.
    Wijnenga MM, Mattni T, French PJ, Rutten G-J, Leenstra S, Kloet F, et al. Does early resection of presumed low-grade glioma improve survival? A clinical perspective. J Neuro-Oncol. 2017;133(1):137–46.Google Scholar
  17. 17.
    Aghi MK, Nahed BV, Sloan AE, Ryken TC, Kalkanis SN, Olson JJ. The role of surgery in the management of patients with diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol. 2015;125(3):503–30.Google Scholar
  18. 18.
    Jakola AS, Myrmel KS, Kloster R, Torp SH, Lindal S, Unsgård G, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA. 2012;308(18):1881–8.PubMedGoogle Scholar
  19. 19.
    Jakola A, Skjulsvik A, Myrmel K, Sjåvik K, Unsgård G, Torp S, et al. Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol. 2017;28(8):1942–8.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Lee S, Choi SH, Ryoo I, Yoon TJ, Kim TM, Lee S-H, et al. Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging. J Neuro-Oncol. 2015;121(1):141–50.Google Scholar
  21. 21.
    Villanueva-Meyer JE, Wood MD, Choi BS, Mabray MC, Butowski NA, Tihan T, et al. MRI features and IDH mutational status of grade II diffuse gliomas: impact on diagnosis and prognosis. Am J Roentgenol. 2018;210(3):621–8.Google Scholar
  22. 22.
    Suh CH, Kim HS, Jung SC, Choi CG, Kim SJ. Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis. Eur Radiol. 2018:1–14.Google Scholar
  23. 23.
    Shaw EG, Berkey B, Coons SW, Bullard D, Brachman D, Buckner JC, et al. Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg. 2008;109(5):835–41.PubMedGoogle Scholar
  24. 24.
    Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26(8):1338–45.PubMedGoogle Scholar
  25. 25.
    Ius T, Isola M, Budai R, Pauletto G, Tomasino B, Fadiga L, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and its impact on overall survival. A single-institution experience in 190 patients. J Neurosurg. 2012;117(6):1039–52.PubMedGoogle Scholar
  26. 26.
    •• Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016;374(14):1344–55 Provides highest level of evidence to guide treatment of low-grade gliomas.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996;36(3):549–56.PubMedGoogle Scholar
  28. 28.
    Van den Bent M, Afra D, De Witte O, Hassel MB, Schraub S, Hoang-Xuan K, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366(9490):985–90.PubMedGoogle Scholar
  29. 29.
    Xia L, Fang C, Chen G, Sun C. Relationship between the extent of resection and the survival of patients with low-grade gliomas: a systematic review and meta-analysis. BMC Cancer. 2018;18(1):48.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol. 2012;30(25):3065–70.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Shaw EG, Berkey B, Coons SW, Bullard D, Brachman D, Buckner JC, et al. Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg. 2008;109(5):835–41.Google Scholar
  32. 32.
    Brown PD, Buckner JC, Uhm JH, Shaw EG. The neurocognitive effects of radiation in adult low-grade glioma patients. Neuro-Oncology. 2003;5(3):161–7.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Khasraw M, Lassman AB. Neuro-oncology: late neurocognitive decline after radiotherapy for low-grade glioma. Nat Rev Neurol. 2009;5(12):646–7.PubMedGoogle Scholar
  34. 34.
    Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-Oncology. 2012;14(suppl_4):iv17–24.PubMedPubMedCentralGoogle Scholar
  35. 35.
    MF MA, Brown PD. Neurocognitive function following therapy for low-grade gliomas. Semin Radiat Oncol. 2015;25(3):210–8 Elsevier.Google Scholar
  36. 36.
    Shaw E, Arusell R, Scheithauer B, O’fallon J, O’neill B, Dinapoli R, et al. Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 2002;20(9):2267–76.PubMedGoogle Scholar
  37. 37.
    Shih HA, Sherman JC, Nachtigall LB, Colvin MK, Fullerton BC, Daartz J, et al. Proton therapy for low-grade gliomas: results from a prospective trial. Cancer. 2015;121(10):1712–9.PubMedGoogle Scholar
  38. 38.
    Bronk JK, Guha-Thakurta N, Allen PK, Mahajan A, Grosshans DR, McGovern SL. Analysis of pseudoprogression after proton or photon therapy of 99 patients with low grade and anaplastic glioma. Clin Transl Radiat Oncol. 2018;9:30–4.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Sherman JC, Colvin MK, Mancuso SM, Batchelor TT, Oh KS, Loeffler JS, et al. Neurocognitive effects of proton radiation therapy in adults with low-grade glioma. J Neuro-Oncol. 2016;126(1):157–64.Google Scholar
  40. 40.
    Proton beam or intensity-modulated radiation therapy in preserving brain function in patients with IDH mutant grade II or III glioma. https://ClinicalTrials.gov/show/NCT03180502. Accessed 19 Dec 2018.
  41. 41.
    Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Coons SW, et al. ACTR-37. Predictive significance of IDH1/2 mutation and 1p/19q co-deletion status in a post-hoc analysis of NRG oncology/rtog 9802: a phase iii trial of RT vs RT + PCV in high risk low-grade gliomas. Neuro-Oncology. 2017;19(suppl_6):vi8–vi.PubMedCentralGoogle Scholar
  42. 42.
    van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344–50.PubMedGoogle Scholar
  43. 43.
    Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337–43.PubMedGoogle Scholar
  44. 44.
    Van den Bent M, Taphoorn M, Brandes AA, Menten J, Stupp R, Frenay M, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol. 2003;21(13):2525–8.PubMedGoogle Scholar
  45. 45.
    Fisher BJ, Hu C, Macdonald DR, Lesser GJ, Coons SW, Brachman DG, et al. Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424. Int J Radiat Oncol Biol Phys. 2015;91(3):497–504.PubMedPubMedCentralGoogle Scholar
  46. 46.
    •• van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 2017;390(10103):1645–53 Provides highest level of evidence to guide treatment of anaplastic gliomas.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Chang S, Zhang P, Cairncross JG, Gilbert MR, Bahary JP, Dolinskas CA, et al. Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG oncology RTOG 9813. Neuro-Oncology. 2017;19(2):252–8.PubMedGoogle Scholar
  48. 48.
    Jaeckle K, Vogelbaum M, Ballman K, Anderson SK, Giannini C, Aldape K, et al. CODEL (alliance-N0577; EORTC-26081/22086; NRG-1071; NCIC-CEC-2): phase III randomized study of RT vs. RT+TMZ vs. TMZ for newly diagnosed 1p/19q-codeleted anaplastic oligodendroglial tumors. Analysis of patients treated on the original protocol design (PL02. 005). Neurology. 2016;86(16 Supplement):PL02.005.Google Scholar
  49. 49.
    Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27(35):5874–80.PubMedGoogle Scholar
  50. 50.
    Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, et al. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro-Oncology. 2011;13(6):649–59.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343(6167):189–93.PubMedGoogle Scholar
  52. 52.
    Combs SE, Thilmann C, Edler L, Debus JR, Schulz-Ertner D. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol. 2005;23(34):8863–9.PubMedGoogle Scholar
  53. 53.
    Pace A, Vidiri A, Galie E, Carosi M, Telera S, Cianciulli A, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol. 2003;14(12):1722–6.PubMedGoogle Scholar
  54. 54.
    Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol. 2003;14(12):1715–21.PubMedGoogle Scholar
  55. 55.
    Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol. 2003;21(4):646–51.PubMedGoogle Scholar
  56. 56.
    • van den Bent MJ, Klein M, Smits M, Reijneveld JC, French PJ, Clement P, et al. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. Lancet Oncol. 2018;19(9):1170–9 RCT that aims to clarify the role of Bevacizumab in the treatment of gliomas.PubMedGoogle Scholar
  57. 57.
    Wahl M, Chang SM, Phillips JJ, Molinaro AM, Costello JF, Mazor T, et al. Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: a phase 2 study of everolimus for recurrent adult low-grade gliomas. Cancer. 2017;123(23):4631–9.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of NeurologyMayo Clinic RochesterRochesterUSA
  2. 2.Department of Medical OncologyMayo Clinic RochesterRochesterUSA

Personalised recommendations